APA
PTPI

American Portfolios Advisors’s Petros Pharmaceuticals PTPI Stock Holding History

American Portfolios Advisors’s Portfolio PTPI Stock Details PTPI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-4
Closed -$4.4K – 3309
2020
Q4 		$4.4K Buy
+4
New +$3.76K ﹤0.01% 2466

Other funds holding PTPI

NP
NorthRock Partners Minneapolis, Minnesota $6.2B AUM 15.8% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AFAS
Acorn Financial Advisory Services Reston, Virginia $753M AUM 36.94% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
SWM
Spire Wealth Management Mclean, Virginia $3.31B AUM 38.78% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
NRS
Neville Rodie & Shaw New York $1.55B AUM 46.95% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return

American Portfolios Advisors's PTPI Position: Q1 2021 in Review

American Portfolios Advisors sold out of Petros Pharmaceuticals (PTPI) in Q1 2021, closing a stake of 4 shares — an estimated $4.4K sold.

American Portfolios Advisors first reported a position in PTPI in Q4 2020 and held it in 1 quarter. The position peaked at $4.4K in Q4 2020. 17 funds tracked by Wall St. Rank hold PTPI as of Q1 2021.

  • American Portfolios Advisors reported no remaining Petros Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • American Portfolios Advisors sold 4 Petros Pharmaceuticals shares in Q1 2021, an estimated $4.4K.
  • American Portfolios Advisors first reported a position in Petros Pharmaceuticals in Q4 2020 and held it in 1 quarter.
  • American Portfolios Advisors's Petros Pharmaceuticals position peaked at $4.4K in Q4 2020.
  • 17 funds tracked by Wall St. Rank held Petros Pharmaceuticals as of Q1 2021.

Based on American Portfolios Advisors's 13F filing for Q1 2021, filed 22 Mar 2023.